FDA lights more fire under smoking-cessation drug Chantix
FDA issues public health advisory on varenicline
After sending out an Early Communication in November 2007 regarding reports of suicidality in patients taking findings, the FDA has asked Pfizer to increase the prominence of the potential serious neuropsychiatric symptoms in the warnings and precautions section of the product's prescribing information. The company will also finalize an official Medication Guide for distribution to patients. Patients should let their healthcare providers know if they have a history of psychiatric illness prior to taking the drug; healthcare professionals should monitor for changes in a patient's mood and behavior during treatment and report immediately to their provider if they occur, according to FDA. Varenicline was approved in 2006 as an aid to smoking cessation.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
